Dr. Sandra Heskamp is an acclaimed researcher at the Radboud Institute for Molecular Life Sciences. As associate professor, she performs pioneering research in the Radiology & Nuclear Medicine department with a focus on immunotherapy and treatment, and rare cancer research.
Over thirty-five scientists at the institute employ MILabs’ SPECT and CT imaging in their research. Using microSPECT/CT, Dr. Heskamp published the first preclinical study ever showing the feasibility of noninvasive in vivo imaging of PD-L1 expression in tumors. This landmark imaging study on immune checkpoint inhibition, is one of the most-referenced articles in the field of anti-PD-1:PD-L1, a research area that according to ResearchGate 2018 is clearly dominating what immunotherapy researchers are reading today.
Read the full article here.
|